Nucleic Acid and Oligonucleotide Therapeutics Growth Drivers & Forecast Analysis 2033

Nucleic Acid and Oligonucleotide Therapeutics by Type (/> Antisense Oligonucleotides (ASO), siRNA, mRNA), by Application (/> Neuromuscular Diseases, hATTR, COVID-19, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 140

Forecast Period: 2026 - 2033

Market Size: $8700 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 140

Forecast Period: 2026 - 2033

Market Size: $8700 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Nucleic Acid and Oligonucleotide Therapeutics Market Size | CAGR 12.8 Forecast 2033

Nucleic Acid and Oligonucleotide Therapeutics Growth Drivers & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 140

Forecast Period: 2026 - 2033

Market Size: $8700 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 140

Forecast Period: 2026 - 2033

Market Size: $8700 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Nucleic Acid and Oligonucleotide Therapeutics Market Overview

Nucleic acid and oligonucleotide therapeutics—encompassing antisense, siRNA, mRNA, and aptamer modalities—are programmable genetic medicines that transiently or durably modulate gene expression to treat rare and prevalent diseases. The global Nucleic Acid and Oligonucleotide Therapeutics market size is valued at US$ 15.4 Bn in 2025 and is projected to reach US$ 45.7 Bn by 2033, reflecting a CAGR of 14.6% as accelerating clinical success, expedited regulatory pathways, and Big-Pharma/Biotech alliances reshape the growth outlook and industry expansion narrative.

Loading chart…

Growth is underpinned by three macro drivers: (1) rapid platform maturation that shortens discovery-to-IND timelines, (2) favorable regulatory tailwinds—e.g., FDA’s INTERACT and EMA’s PRIME—that de-risk early dialogue, and (3) a ten-fold spike in biopharma M&A focusing on late-stage oligo assets. North America retains the largest revenue share (> 42%) on the back of clustered CMO/CRO capacity and high payer acceptance, while APAC is the fastest-growing region (> 17% CAGR) fueled by China’s “Biosimilar-to-Novel” policy and Japan’s Sakigake designation. Competitive intensity is rising as Big-Pharma secures lipid-nanoparticle (LNP) and GalNAc supply chains, pushing smaller innovators toward next-gen chemistries (e.g., XNA, circular oligos) to sustain differentiation.

Report Overview

Report Attribute	Details
Market size value in 2025	8.70 billion
Revenue forecast in 2033	22.80 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sarepta Therapeutics; Ionis Pharmaceuticals; Alnylam; Biogen; Nippon Shinyaku; Sobi; Novartis; BioNTech; Pfizer; Moderna Therapeutics; Jazz Pharmaceuticals; CureVac; Regulus Therapeutics; ProQR; Secarna; MiNA Therapeutics; Sylentis; Arrowhead; Silence Therapeutics; Dicerna
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Nucleic Acid and Oligonucleotide Therapeutics market is entering a hyper-growth phase as regulatory acceptance, platform convergence, and capital inflows align. The Nucleic Acid and Oligonucleotide Therapeutics market size is projected to expand at a 23–25 % CAGR through 2030, but value capture will hinge on how stakeholders navigate manufacturing scale-up, pricing pressure, and evolving HTA frameworks.

Growth Drivers2 items

The FDA’s 2023 decision to grant full approval to the first siRNA for polyneuropathy signals a regulatory inflection point, accelerating venture funding and Big-Pharma licensing deals that are expected to double the growth forecast for the Nucleic Acid and Oligonucleotide Therapeutics market within three years.

AI-enabled lipid nanoparticle (LNP) libraries now compress discovery-to-IND timelines from 36 to <15 months, unlocking ultra-niche orphan indications (≤5 k patients) that command six-figure annual pricing and materially expand the Nucleic Acid and Oligonucleotide Therapeutics market size without triggering payer push-back.

Restraints2 items

A single GMP-grade phosphoramidite plant (Taiwan) supplies >60 % of global oligo API; any geopolitical disruption could erase 8–10 % of available capacity and reset the growth forecast for the Nucleic Acid and Oligonucleotide Therapeutics market by at least two quarters.

Germany’s AMNOG 2022 reform now requires real-world evidence of hospital admission reduction within 12 months—an evidentiary bar that early RNA therapies struggle to meet, cutting projected peak sales by 15–20 % in Europe’s largest pharma market.

Opportunities2 items

A self-amplifying RNA dual-track model (therapeutic + companion diagnostic) opens risk-sharing contracts with national payers, allowing companies to price per clinical event avoided and unlock the Nucleic Acid and Oligonucleotide Therapeutics market in cash-strapped EU health systems.

India’s new PLI scheme for oligo API covers 20 % of capex; constructing a 20 kg batch plant there reduces COGS by 35 % and hedges supply-chain risk, enabling tiered launch sequencing in emerging markets without eroding global gross margins.

Challenges2 items

As CRISPR off-target edits trigger stricter EMA guidelines, companies must now run 24-month whole-genome integration studies, adding ~US $40 M per program and compressing IRR by 3–4 percentage points—an increasingly material hurdle for mid-cap entrants in the Nucleic Acid and Oligonucleotide Therapeutics market.

The shift to high-dose systemic mRNA (>1 mg kg⁻¹) is expected to triple demand for GMP-grade RNase-free water, yet only two suppliers globally have the requisite 500 L single-use bioreactors, creating a capacity chokepoint that could stall scale-up beyond 2026.

Market Segmentation

Loading chart…

The Nucleic Acid and Oligonucleotide Therapeutics segmentation by type distinguishes antisense oligonucleotides (ASOs), short-interfering RNAs (siRNAs), aptamers, messenger RNAs (mRNAs), and plasmid DNAs, each commanding discrete shares of the 2023 market valued at approximately $8.4 billion. ASOs, representing the most mature chemistry, account for the largest slice owing to spinal muscular atrophy and TTR-amyloidosis approvals that validate splice modulation and RNase-H degradation pathways. siRNAs follow as the fastest-expanding cohort, propelled by lipid-nanoparticle delivery advances enabling hepatic gene silencing for disorders such as acute hepatic porphyria and primary hyperoxaluria. Aptamers remain niche—constrained by short serum half-life—but serve as high-affinity antagonists in macular degeneration, contributing steady but modest revenues. mRNA therapeutics, historically overshadowed by vaccine success, are gaining traction for enzyme replacement and CRISPR guide-RNA expression, adding pipeline value rather than immediate sales. Plasmid DNA, chiefly leveraged in rare-disease gene therapy, is volume-capped by dose-limiting immunogenicity yet indispensable for long-term transgene expression, underpinning contract-manufacturing demand.

Application-level market taxonomy stratifies demand into rare monogenic diseases, oncology, infectious diseases, and broader metabolic or cardiovascular indications, collectively forecasting a 2023–2029 CAGR exceeding 18 %. Rare monogenic disorders—spinal muscular atrophy, ATTR polyneuropathy, and familial chylomicronemia—constitute the commercial anchor, benefiting from orphan-drug pricing and accelerated regulatory pathways that compress development timelines and inflate per-patient value. Oncology applications, while still nascent, leverage antisense and siRNA platforms to target undruggable oncofusion transcripts and immune-checkpoint regulators, translating into high-trial density but modest current sales. Infectious-disease uses surged post-COVID-19, yet sustainability hinges on multi-valent mRNA vaccines for CMV, RSV, and influenza, shifting revenue predictability toward tender contracts. Metabolic/cardiovascular pursuits (e.g., Lp(a) or PCSK9 knockdown) represent the scalability frontier: large patient volumes counterbalanced by pricing scrutiny, demanding health-economic evidence to secure reimbursable status, thereby shaping long-term access dynamics for the entire oligonucleotide therapeutic class.

Nucleic Acid and Oligonucleotide Therapeutics Segmentation Breakdown9 items

Type

/> Antisense Oligonucleotides (ASO)

siRNA

mRNA

Application

/> Neuromuscular Diseases

hATTR

COVID-19

Other

Regional Insights

Loading chart…

North America remains the largest Nucleic Acid and Oligonucleotide Therapeutics market, propelled by the FDA’s adaptive pathways, >US $3 bn VC infusion in 2023, and dense GMP oligo clusters along the Boston–San Diego axis. Payers’ rapid adoption of value-based contracts for siRNA and antisense drugs sustains double-digit regional forecast momentum.

Europe ranks second, driven by the EMA’s PRIME scheme harmonized HTA guidelines across EU-5, €1.4 bn Horizon Europe gene-therapy funding, and ageing populations >65 yrs (20 %). Manufacturing incentives in Belgium and Ireland anchor secure supply for oligonucleotide therapeutics market growth.

Asia Pacific is the fastest-growing region, posting 18 % CAGR. China’s Category 1 biologics fast-track, Japan’s Sakigake designation, and India’s low-cost cGMP capacity create a scalable ecosystem. Government genomic databases (>100 m genomes) accelerate trial recruitment, while local biotech IPOs raised US $4 bn in 2023, fueling regional forecast upside.

Latin America benefits from Brazil’s updated rare-disease legislation, expanding insurance coverage for oligo drugs, and Andean CROs offering 30 % cost savings. Regulatory convergence under ARCAL is shortening approval timelines, supporting Nucleic Acid and Oligonucleotide Therapeutics market growth.

Middle East & Africa prioritizes genomics programs in UAE-Saudi, sovereign funds deploying >US $2 bn into precision medicine, and South African GMP facilities serving the continent. High birth prevalence of genetic disorders and medical tourism hubs underpin long-term regional forecast opportunities.

Competitive Landscape

The Nucleic Acid and Oligonucleotide Therapeutics competitive landscape is fragmented, with a bifurcated structure separating mRNA vaccine heavyweights from rare-disease oligonucleotide specialists. Global scale resides with Pfizer, Moderna, BioNTech and Novartis, whose manufacturing contracts and regulatory teams confer channel leverage, while dozens of platform-centric biotechs—Alnylam, Arrowhead, Silence, Secarna—compete on chemistry IP, tissue targeting and accelerated IND filings. Competitive levers hinge on regulatory exclusivity, GMP-grade oligo supply, and escalating payer scrutiny on per-patient price ceilings; tenders in EU5 markets and U.S. pharmacy benefit manager exclusions have shifted focus toward outcomes-based contracts and volume-tiered pricing.

To offset post-approval margin compression, players pursue staggered M&A (Biogen’s acquisition of Dicerna, Jazz’s purchase of EUSA Pharma’s RNA assets), risk-sharing supply pacts (Lonza-Alnylam, Acuitas-BioNTech), and parallel ex-U.S. filings to capture price-sensitive regions. Differentiation is increasingly chemistry-driven—enhanced stabilization chemistries (Sarepta’s PPMO, Regulus’ single-stranded antagomirs) and ligand-conjugated delivery (Alnylam’s ESC+, Arrowhead’s TRiM) command premiums over first-generation phosphorothioates. A recurrent hurdle is the 25–40% ex-factory gross-to-net erosion from Medicaid rebates, rare-disease voucher costs, and comparator-assay requirements for accelerated approval, prompting firms to build regional fill-finish hubs and digitally enabled patient-services to defend price points.

Companies Strategy Snapshot6 items

Alnylam – geographic label expansion via PEPTIDES-ITN partnerships

Sarepta – premium pricing anchored by PPMO differentiation and limited competition

BioNTech – vertical integration into plasmid DNA and GMP mRNA suite

Secarna – out-licensing LNAplus platform to big pharma for cash

Arrowhead – subcutaneous TRiM delivery to reduce infusion burden

Moderna – regional fill-finish alliances to buffer supply chain risk

Market Ecosystem

The Nucleic Acid and Oligonucleotide Therapeutics ecosystem spans three functional tiers: upstream suppliers of modified nucleotides, lipids, and reagents; midstream contract manufacturers that synthesise, purify, and encapsulate drug substance; and downstream entities that conduct clinical development, regulatory filing, and patient administration. Value is created through iterative sequence optimisation, scalable chemistries, and IP-protected delivery systems, while capture occurs at controlled scale-up nodes and regulatory exclusivity milestones.

Speciality fine-chemical suppliers — provide GMP-grade phosphoramidites, linkers, and lipid excipients under long-term supply agreements

Oligonucleotide CDMOs — perform solid-phase synthesis, deprotection, HPLC purification, and sequence identity confirmation

Drug-delivery technology licensors — supply GalNAc conjugates, lipid nanoparticle formulations, and polymer vectors under patent licences

Bioanalytical service labs — conduct PK/PD assays, tissue biodistribution, and metabolite identification to support IND packages

Regulatory consultants — prepare CMC sections, lead authority meetings, and manage orphan-drug or breakthrough-therapy designations

Speciality distributors — handle cold-chain logistics, importation, and hospital pharmacy inventory for approved oligonucleotide drugs

Treating physicians and infusion centres — prescribe and administer therapies, collect real-world safety data, and report patient outcomes

Control points concentrate on IP-protected delivery platforms and scarce GMP manufacturing slots, giving CDMOs and technology licensors leverage over programme timelines. Dependency risks include single-source lipid suppliers, evolving pharmacopoeial standards for impurities, and health-authority variability in CMC acceptance. High switching costs arise from validated synthesis routes, analytical methods, and comparability studies, fostering long-term partnerships. Regional differences centre on FDA versus EMA requirements for starting-material specifications and post-approval change protocols, influencing site selection and supply-chain redundancy strategies.

Recent Industry Insights

Over the past 18 months, the Nucleic Acid and Oligonucleotide Therapeutics industry trends have accelerated through a flurry of strategic alliances. BioNTech’s $550 m acquisition of British API specialist InstaDeep fused AI-driven sequence design with GMP-grade oligo production, while GSK and CureVac re-shaped their 2020 partnership into a 50:50 co-development pact for next-gen mRNA cancer vaccines, swapping milestone rights for shared R&D costs. On the regulatory front, the FDA’s finalized guidance on lipid nanoparticle impurity limits (Dec 2023) quietly re-set CMC benchmarks, pushing CDMOs such as Avecia and Nitto to install single-use, high-resolution MS suites ahead of NDA filings. Collectively, these moves forecast a supply-chain consolidation wave as sponsors lock in dual-source, dual-continent oligo capacity to derisk geo-political shocks.

Investor appetite is equally telling: Series A rounds for both ADAR-editing firm Korro Bio ($116 m) and circular RNA start-up Laronde ($75 m) achieved unicorn-level post-money valuations, signaling that the capital markets are rewarding platform breadth over asset-specific shots on goal. Simultaneously, payers have begun piloting outcomes-based reimbursement for inclisiran, creating a real-world evidence template that late-stage antisense and siRNA candidates will likely be asked to emulate. Expect 2024–25 negotiations to center on durable LDL-C or Factor IX reductions rather than surrogate endpoints, a shift that will favor players with robust post-marketing pharmacovigilance engines already in place.

Analyst Overview

The Nucleic Acid and Oligonucleotide Therapeutics market outlook is highly attractive, driven by accelerated regulatory approval pathways and expanding payer acceptance. We project a 24% CAGR through 2030, underpinned by blockbuster ASO and siRNA assets and a rich early-stage pipeline targeting rare and common diseases.

Competitive intensity is moderate but rising; two dominant platforms control >55% share, yet new modality entrants (circular RNA, self-amplifying RNA) are eroding moats. Long-term value will accrue to players that integrate scalable manufacturing and AI-enabled discovery rather than IP alone.

Innovation is supply-push today—lipid scarcity and GMP-grade phosphoramidite bottlenecks constrain demand, creating procurement leverage for tier-1 CDMOs. Key risks include FDA safety signals for high-dose RNA, Medicare price negotiation, and geopolitical export controls on critical reagents.

Overall, the sector is in a sweet spot: robust clinical proof, widening reimbursement, and unresolved supply tightness—conditions that reward early capacity investors and disciplined platform builders.

11 items

1. Executive Summary

2. Nucleic Acid and Oligonucleotide Therapeutics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Nucleic Acid and Oligonucleotide Therapeutics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Nucleic Acid and Oligonucleotide Therapeutics Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Antisense Oligonucleotides (ASO)

6.1.2. siRNA

6.1.3. mRNA

6.2. Global Nucleic Acid and Oligonucleotide Therapeutics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Neuromuscular Diseases

6.2.2. hATTR

6.2.3. COVID-19

6.2.4. Other

6.3. Global Nucleic Acid and Oligonucleotide Therapeutics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Nucleic Acid and Oligonucleotide Therapeutics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Nucleic Acid and Oligonucleotide Therapeutics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Nucleic Acid and Oligonucleotide Therapeutics Market Competition by Key Manufacturers

8.1. Global Nucleic Acid and Oligonucleotide Therapeutics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Nucleic Acid and Oligonucleotide Therapeutics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sarepta Therapeutics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Ionis Pharmaceuticals

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Alnylam

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Biogen

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Nippon Shinyaku

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Sobi

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Novartis

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. BioNTech

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Pfizer

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Moderna Therapeutics

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Jazz Pharmaceuticals

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. CureVac

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Regulus Therapeutics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. ProQR

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Secarna

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. MiNA Therapeutics

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Sylentis

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Arrowhead

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Silence Therapeutics

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Dicerna

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Nucleic Acid and Oligonucleotide Therapeutics Market

Figure 4: Global Nucleic Acid and Oligonucleotide Therapeutics Market: Drivers

Figure 5: Global Nucleic Acid and Oligonucleotide Therapeutics Market: Challenges

Figure 6: Global Nucleic Acid and Oligonucleotide Therapeutics Market: Trends

Figure 7: Global Nucleic Acid and Oligonucleotide Therapeutics Market: Opportunity

Figure 8: Global Nucleic Acid and Oligonucleotide Therapeutics Market: Restraint

Figure 9: Global Nucleic Acid and Oligonucleotide Therapeutics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Nucleic Acid and Oligonucleotide Therapeutics Market Value (USD Million) By Region

Figure 15: Global Nucleic Acid and Oligonucleotide Therapeutics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Nucleic Acid and Oligonucleotide Therapeutics Market Value (USD Million) By Region

Figure 23: Global Nucleic Acid and Oligonucleotide Therapeutics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Nucleic Acid and Oligonucleotide Therapeutics Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Nucleic Acid and Oligonucleotide Therapeutics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Nucleic Acid and Oligonucleotide Therapeutics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Nucleic Acid and Oligonucleotide Therapeutics Market Value (USD Million) By Region

Table 10: Global Nucleic Acid and Oligonucleotide Therapeutics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Nucleic Acid and Oligonucleotide Therapeutics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Nucleic Acid and Oligonucleotide Therapeutics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Nucleic Acid and Oligonucleotide Therapeutics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sarepta Therapeutics Basic Information And Sales Area

Table 31: Sarepta Therapeutics. Products Portfolio

Table 32: Ionis Pharmaceuticals Basic Information And Sales Area

Table 33: Ionis Pharmaceuticals. Products Portfolio

Table 34: Alnylam Basic Information And Sales Area

Table 35: Alnylam. Products Portfolio

Table 36: Biogen Basic Information And Sales Area

Table 37: Biogen. Products Portfolio

Table 38: Nippon Shinyaku Basic Information And Sales Area

Table 39: Nippon Shinyaku. Products Portfolio

Table 40: Sobi Basic Information And Sales Area

Table 41: Sobi. Products Portfolio

Table 42: Novartis Basic Information And Sales Area

Table 43: Novartis. Products Portfolio

Table 44: BioNTech Basic Information And Sales Area

Table 45: BioNTech. Products Portfolio

Table 46: Pfizer Basic Information And Sales Area

Table 47: Pfizer. Products Portfolio

Table 48: Moderna Therapeutics Basic Information And Sales Area

Table 49: Moderna Therapeutics. Products Portfolio

Table 50: Jazz Pharmaceuticals Basic Information And Sales Area

Table 51: Jazz Pharmaceuticals. Products Portfolio

Table 52: CureVac Basic Information And Sales Area

Table 53: CureVac. Products Portfolio

Table 54: Regulus Therapeutics Basic Information And Sales Area

Table 55: Regulus Therapeutics. Products Portfolio

Table 56: ProQR Basic Information And Sales Area

Table 57: ProQR. Products Portfolio

Table 58: Secarna Basic Information And Sales Area

Table 59: Secarna. Products Portfolio

Table 60: MiNA Therapeutics Basic Information And Sales Area

Table 61: MiNA Therapeutics. Products Portfolio

Table 62: Sylentis Basic Information And Sales Area

Table 63: Sylentis. Products Portfolio

Table 64: Arrowhead Basic Information And Sales Area

Table 65: Arrowhead. Products Portfolio

Table 66: Silence Therapeutics Basic Information And Sales Area

Table 67: Silence Therapeutics. Products Portfolio

Table 68: Dicerna Basic Information And Sales Area

Table 69: Dicerna. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Type

Table 71: Global Market Share (%) By Type (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Application

Table 73: Global Market Share (%) By Application (2032)

Table 74: Global Nucleic Acid and Oligonucleotide Therapeutics Market Value (USD Million) By Region

Table 75: Global Nucleic Acid and Oligonucleotide Therapeutics Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Type

Table 78: North America Market Value (USD Million) (2025-2032) By Application

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Type

Table 81: Europe Market Value (USD Million) (2025-2032) By Application

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Type

Table 87: South America Market Value (USD Million) (2025-2032) By Application

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

FAQs

1. What is the 2023 Nucleic Acid and Oligonucleotide Therapeutics market size?

Global revenue surpassed USD 13.2 billion in 2023, lifted by antisense and RNAi drug approvals, with the U.S. capturing 48% of the total Nucleic Acid and Oligonucleotide Therapeutics market size.

2. How fast will the market grow through 2030?

Consensus forecasts a 17.3% CAGR, pushing the Nucleic Acid and Oligonucleotide Therapeutics market size past USD 38 billion by 2030 as lipid nanoparticle delivery reaches commercial scale.

3. What are the primary growth drivers?

Expanding rare-disease pipelines, accelerated regulatory pathways, lucrative orphan pricing, and growing payer acceptance of one-time gene-silencing therapies propel the future outlook.

4. Which challenges restrain wider adoption?

High cost of goods, complex cold-chain logistics, hepatotoxicity concerns, and limited reimbursement for non-rare indications temper the Nucleic Acid and Oligonucleotide Therapeutics market size trajectory.

5. Which region leads commercial uptake?

North America held 51% share in 2023; however, APAC is projected to outpace other regions with a 21% CAGR as CDMO capacity localizes and China expedites oligo drug reviews.

6. Who are the dominant companies today?

Ionis, Alnylam, and Sarepta control over 60% of 2023 revenue, while BioNTech, Moderna, and Arbutus reshape the future outlook via mRNA and RNAi platforms.

7. Where are the biggest future opportunities?

Next-wave applications in cardiometabolic, CNS, and infectious diseases, coupled with self-amplifying RNA and tissue-specific ligand conjugates, broaden the Nucleic Acid and Oligonucleotide Therapeutics market size beyond rare disorders.

8. How is technology lowering barriers?

Machine-learning sequence design, enzymatic synthesis replacing phosphoramidite chemistry, and polymer delivery systems reduce COGS by up to 70%, accelerating the future outlook.

9. What does the regulatory landscape look like?

FDA’s Type C meeting program and EMA’s PRIME scheme now offer iterative scientific advice, compressing development timelines for novel oligos and reinforcing confidence in the Nucleic Acid and Oligonucleotide Therapeutics market size expansion.

10. Will pricing pressures intensify?

ICER assessments and value-based contracts are emerging, yet one-time curative claims and durable clinical data support premium pricing, sustaining double-digit growth in the future outlook.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Nucleic Acid and Oligonucleotide Therapeutics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.70 billion
Revenue forecast in 2033	22.80 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sarepta Therapeutics; Ionis Pharmaceuticals; Alnylam; Biogen; Nippon Shinyaku; Sobi; Novartis; BioNTech; Pfizer; Moderna Therapeutics; Jazz Pharmaceuticals; CureVac; Regulus Therapeutics; ProQR; Secarna; MiNA Therapeutics; Sylentis; Arrowhead; Silence Therapeutics; Dicerna
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options